Johnson & Johnson (JNJ)
177.94
+1.69 (0.96%)
NYSE · Last Trade: Aug 19th, 3:36 PM EDT
Detailed Quote
Previous Close | 176.25 |
---|---|
Open | 176.04 |
Bid | 177.93 |
Ask | 177.95 |
Day's Range | 175.98 - 178.18 |
52 Week Range | 140.68 - 177.57 |
Volume | 6,216,632 |
Market Cap | 467.75B |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 5.200 (2.92%) |
1 Month Average Volume | 8,499,101 |
Chart
About Johnson & Johnson (JNJ)
Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
News & Press Releases
Despite hovering at or near all-time highs, the major U.S. stock indices—the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite—have recently displayed a remarkably subdued daily performance. This period of consolidation, marked by narrow trading ranges and fractional movements, signals a market grappling with a
Via MarketMinute · August 19, 2025
The U.S. Treasury yield curve has contorted into a rare and unsettling U-shape, a configuration seen in only a fraction of the past five decades. This unusual curve, characterized by high short-term rates, a distinct dip in intermediate-term yields, and a subsequent rise for longer maturities, signals a profound
Via MarketMinute · August 19, 2025
Wall Street is currently gripped by a palpable "wait-and-see" sentiment, as investors adopt an overwhelmingly cautious stance ahead of Federal Reserve Chair Jerome Powell's highly anticipated speech at the Jackson Hole Symposium. This pervasive mood has led to muted trading activity across major indices, reflecting a deep-seated reluctance among market
Via MarketMinute · August 19, 2025
Carlsmed secures NTAP reimbursement and FDA support, while BofA projects strong revenue growth and assigns a Buy rating with a $16 target.
Via Benzinga · August 18, 2025
Via Benzinga · August 18, 2025
The global financial landscape is currently navigating a period of heightened uncertainty, with key economic indicators signaling a notable deceleration in private consumption and emerging fragilities within the labor market. These intertwined trends are casting a long shadow over the stock market, prompting investors to re-evaluate their positions and brace
Via MarketMinute · August 18, 2025

These companies have successfully navigated similar obstacles before.
Via The Motley Fool · August 17, 2025
These three dividend stocks offer steady income and a history of delivering through thick and thin.
Via The Motley Fool · August 16, 2025
Washington D.C. – Hopes for an imminent Federal Reserve interest rate cut have significantly dimmed following the release of hotter-than-expected Producer Price Index (PPI) data on August 14, 2025. The July PPI report revealed a surprising surge in wholesale inflation, forcing traders and economists to reconsider the widespread expectation of
Via MarketMinute · August 14, 2025
The financial markets are currently experiencing a significant sector rotation, as investors increasingly shift their capital from growth-oriented technology stocks towards more value-driven cyclical sectors. This strategic reallocation of assets reflects a broader recalibration of market expectations, signaling a potential late-stage economic cycle or an environment characterized by persistent inflation.
Via MarketMinute · August 14, 2025
The financial markets are once again grappling with the persistent specter of inflation, as the latest reports have sent ripples through the bond market and currency exchange rates. Following a series of economic data releases, the yield on the benchmark 10-year Treasury note has seen a notable climb, while the
Via MarketMinute · August 14, 2025
The United States economy presented a complex and somewhat contradictory picture in the second quarter of 2025, demonstrating a robust 3.0% annualized Gross Domestic Product (GDP) growth, a significant rebound from the previous quarter's contraction. This headline figure suggests a resilient economy, defying some predictions of an imminent slowdown.
Via MarketMinute · August 14, 2025
Palantir Technologies is priced for perfection. Unfortunately, no situation on Wall Street is ever perfect.
Via The Motley Fool · August 14, 2025
The financial markets are abuzz with heightened expectations for a Federal Reserve interest rate cut in September, with probabilities soaring to an overwhelming 96%. This dramatic shift in sentiment comes on the heels of recent inflation data, particularly the July Consumer Price Index (CPI) report, which has largely been interpreted
Via MarketMinute · August 13, 2025
Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's disease.
Via Benzinga · August 13, 2025
If you have decades to go before you retire, you want to make sure you own companies that know how to survive and thrive.
Via The Motley Fool · August 13, 2025
Via The Motley Fool · August 12, 2025
Dip into a beaten-down market sector for deals on some proven winners.
Via The Motley Fool · August 12, 2025
Economists and investors are increasingly sounding the alarm over the growing risk of "stagflation," a perilous economic phenomenon characterized by high inflation coupled with stagnant economic growth. At the heart of these concerns are the tariff policies enacted by former President Donald Trump, which many experts fear could simultaneously drive
Via MarketMinute · August 11, 2025
Novartis' ianalumab showed significant disease activity improvement in two Phase 3 Sjögren's trials, supporting plans for global health authority filings.
Via Benzinga · August 11, 2025
Three major dividend names—Waste Management, Eversource, and Johnson & Johnson—each gave investors new reasons to keep them in mind thanks to recent earnings.
Via MarketBeat · August 11, 2025
Volatility is back in the markets, and jobs data points to a weakening labor market. Is it time to get defensive? Consider these 3 dividend stocks for income.
Via MarketBeat · August 11, 2025
These top dividend stocks should deliver strong total returns over the next half-decade.
Via The Motley Fool · August 9, 2025
These stocks check off all the boxes for investors no longer receiving a paycheck.
Via The Motley Fool · August 9, 2025
This ultra-low-cost ETF is an excellent way to invest in large-cap value stocks, many of which pay dividends.
Via The Motley Fool · August 9, 2025